Hospital Universitario Puerta De Hierro De Majadahonda

This site supports a broad portfolio of cancer trials across solid tumors and blood cancers, with a strong focus on improving treatment options for non-small cell lung cancer, breast cancer, prostate cancer, and gastrointestinal malignancies. Many studies are designed to test new therapies, compare them with current standards, and improve outcomes for people with advanced or high-risk disease.

• Non-small cell lung cancer research includes studies in early-stage, locally advanced, and metastatic disease, often aiming to extend survival and reduce recurrence.
• Breast cancer trials cover hormone receptor-positive, HER2-positive, HER2-low, and triple-negative disease, with a focus on better disease control and relapse prevention.
• Hematologic malignancies such as chronic lymphocytic leukemia, lymphoma, and multiple myeloma are being studied to improve response rates and long-term disease management.

The research activity at Hospital Universitario Puerta De Hierro De Majadahonda also reflects a strong commitment to evaluating newer immunotherapy, targeted therapy, and combination approaches across difficult-to-treat cancers.

A major part of the clinical trial program focuses on respiratory diseases, especially asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pulmonary hypertension. These studies aim to improve symptom control, slow disease progression, and evaluate new treatment strategies for patients with chronic lung conditions.

• Asthma and allergic rhinoconjunctivitis studies are exploring better control of inflammation and day-to-day symptoms.
• COPD and chronic bronchitis trials are assessing ways to improve breathing and overall clinical stability.
• Idiopathic pulmonary fibrosis and related fibrotic lung diseases are being studied to slow progression and preserve lung function.

The site also investigates serious infections and transplant-related lung complications, showing a broad interest in both chronic and complex respiratory care.

Clinical trials here address a wide range of heart disease and metabolic disorders, including heart failure, hypertrophic cardiomyopathy, atherosclerotic cardiovascular disease, and hypercholesterolemia. The overall goal is to improve cardiovascular outcomes, reduce complications, and test new approaches for patients with high-risk disease.

• Studies in heart failure and cardiomyopathy are evaluating better ways to support heart function and reduce worsening symptoms.
• Research on coronary disease and valvular heart disease is focused on safer and more effective treatment strategies.
• Lipid disorders and resistant hypertension trials are testing improved risk reduction and blood pressure control.

This cardiovascular portfolio also includes studies in transthyretin amyloidosis, reflecting interest in less common but serious heart conditions.

The site has substantial research in liver disease, inflammatory bowel disease, and kidney disorders. Trials are studying ulcerative colitis, Crohn’s disease, nonalcoholic steatohepatitis, cirrhosis, and chronic kidney disease, with the aim of improving disease control, protecting organ function, and reducing long-term complications.

• Inflammatory bowel disease studies are testing new ways to achieve remission and improve intestinal healing.
• Liver disease research includes trials in NASH, hepatocellular carcinoma, and other chronic liver conditions.
• Kidney disease studies focus on IgA nephropathy, proteinuria, and preserving renal function over time.

These investigations highlight a strong interest in both inflammatory and fibrosis-related disease mechanisms.

Clinical research at this hospital also spans neurologic disorders, autoimmune disease, and skin conditions. Studies include multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, atopic dermatitis, lupus, and other immune-mediated diseases, with a focus on improving symptom control and long-term quality of life.

• Multiple sclerosis trials are exploring better control of disease activity and progression.
• Autoimmune neuropathy studies aim to reduce disability and improve nerve-related function.
• Atopic dermatitis and other skin inflammatory disorders are being studied to ease symptoms and maintain longer-lasting control.

The research mix at Hospital Universitario Puerta De Hierro De Majadahonda shows a broad commitment to immune-related diseases that affect multiple organs and body systems.

Another important area of study includes eye disease, infection, and transplant-related care. Trials are evaluating age-related macular degeneration, diabetic macular edema, dry eye disease, tuberculosis, hepatitis B, and transplant complications, with the purpose of improving disease prevention, treatment effectiveness, and long-term safety.

• Retinal disease research is focused on preserving vision in degenerative and diabetic eye conditions.
• Infectious disease studies include viral, bacterial, and fungal conditions that remain difficult to treat.
• Transplant medicine trials address infection prevention and complications after lung transplant and stem cell transplant.

This diverse portfolio reflects the site’s wide clinical reach beyond oncology, while still maintaining a strong focus on complex, high-need patient groups.